TreatSMA

SMA Poland set up operation to help SMA families in Ukraine

This is a operation setup to help SMA families in Ukraine by SMA Poland.

It went live this morning on the 27th February 2022.

The link below has been shared with us, it has further details and has been written in Ukrainian.

There is now a resource centre setup by SMA Poland for Ukrainian SMA families who are fleeing to Poland. They ask that those fleeing read the information and contact them at any time, possibly before travel.

A contact centre has been staffed by Ukrainian, Russian and Polish speaking volunteers (SMA moms) who guide and advise.

Another team member will collect information about travel options – such as free seats in cars or buses. They will then connect with families and paperwork prepared for border crossing.

The contact centre volunteers, also arrange accommodation and also advise on treatment access in Poland.

Travel and accommodation costs will be covered.

You can get more information and contact details on this link https://www.fsma.pl/ukraina/

 

 

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more